ADC Therapeutics SA (ADCT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ADC Therapeutics SA (ADCT) Healthcare & Pipeline Overview

ADC Therapeutics S.A. is a commercial-stage biotechnology firm based in Switzerland, focused on developing proprietary antibody drug conjugates (ADCs) for oncology. The company's pipeline targets hematological malignancies and solid tumors, with its flagship product, ZYNLONTA, advancing through late-stage clinical trials for various lymphoma indications.

What Is the Investment Thesis for ADCT?

ADC Therapeutics S.A. presents a research profile centered on its commercial-stage status and a specialized focus on antibody drug conjugates (ADCs) for oncology. The company's value drivers include its advanced pipeline, particularly ZYNLONTA, which is in Phase II and Phase III clinical trials for significant lymphoma indications, offering potential for market expansion and revenue growth. The gross margin of 90.7% indicates strong pricing power and cost efficiency on its existing revenue streams, a positive operational metric for a biotechnology firm. Strategic collaborations with established pharmaceutical partners provide validation, potential funding, and broader development capabilities. Key growth catalysts include successful clinical trial readouts, regulatory approvals for ZYNLONTA and other pipeline assets, and the progression of earlier-stage candidates like camidanlumab tesirine into later phases. However, the company's negative profit margin of -173.0% underscores the substantial R&D investments typical of biotech, and its Beta of 1.97 suggests higher volatility compared to the broader market, reflecting inherent risks associated with drug development and commercialization.

Based on FMP financials and quantitative analysis

ADCT Key Highlights

ADC Therapeutics is a commercial-stage biotechnology company focused on developing Antibody Drug Conjugates (ADCs) for hematological malignancies and solid tumors.

• The flagship product, ZYNLONTA, is in advanced clinical trials, including Phase III for relapsed or refractory DLBCL, indicating significant market potential.
• The company maintains a robust gross margin of 90.7%, reflecting strong operational efficiency on its current product offerings.
• ADC Therapeutics boasts a diverse pipeline with multiple candidates, such as camidanlumab tesirine, ADCT-602, ADCT-601, and ADCT-901, targeting various cancers in different clinical stages.
• Strategic collaboration and license agreements with partners like Genmab A/S and Mitsubishi Tanabe Pharma Corporation enhance its R&D capabilities and market reach.

Who Are ADCT's Competitors?

ADCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ADCT's Key Strengths?

Commercial-stage status with flagship product ZYNLONTA in advanced clinical trials for significant lymphoma indications.

• Diverse pipeline of Antibody Drug Conjugates (ADCs) targeting both hematological malignancies and solid tumors.
• Strong gross margin of 90.7% on existing revenue streams, indicating efficient cost management for products.
• Strategic collaboration and licensing agreements with multiple pharmaceutical and biotech partners, enhancing R&D capabilities and market reach.

What Are ADCT's Weaknesses?

Significant negative profit margin of -173.0%, reflecting substantial ongoing research and development expenses typical for a biotech company.

• High dependence on the successful outcomes of clinical trials for pipeline candidates, particularly ZYNLONTA and camidanlumab tesirine.
• High Beta of 1.97, indicating greater stock price volatility compared to the broader market, which can deter some investors.
• Limited commercial product portfolio currently, with a heavy reliance on a few lead candidates for future revenue generation.

What Could Drive ADCT Stock Higher?

ADCT catalyst: Potential positive data readouts from ZYNLONTA's Phase III clinical trial for relapsed or refractory DLBCL in second-line transplant-ineligible patients, expected to influence future regulatory submissions.

• Regulatory submissions and potential market approvals for ZYNLONTA in new indications or geographic regions, following successful clinical trial completion.
• Advancement of camidanlumab tesirine into later-stage clinical trials (e.g., Phase III) for Hodgkin lymphoma or solid tumors, signaling progress in pipeline diversification.
• Continued progress and positive data from early-stage clinical trials for candidates such as ADCT-602 (acute lymphoblastic leukemia) and ADCT-601/ADCT-901 (solid tumors), validating the broader ADC platform.
• Announcement of new strategic collaboration or licensing agreements that could provide additional funding, expand market access, or enhance technological capabilities.

What Are the Key Risks for ADCT?

Financial-distress signal — its Altman Z-Score of -8.27 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $19.6M recently.
• Clinical trial failures or unexpected delays for key pipeline candidates, including ZYNLONTA and camidanlumab tesirine, which could significantly impact future revenue and market perception.
• Regulatory setbacks, such as failure to obtain market approval for new indications or drugs, or withdrawal of existing approvals due to safety concerns.
• Intense competition within the oncology and Antibody Drug Conjugate (ADC) therapeutic areas from larger, more established pharmaceutical companies with greater resources.
• Significant capital requirements for continued research, development, and commercialization, potentially leading to future equity dilution or the need for additional financing given the negative profit margin.
• Intellectual property challenges, including patent expiration, infringement claims, or the inability to secure new patents for innovative ADC technologies, which could erode competitive advantage.

What Are the Growth Opportunities for ADCT?

• **ZYNLONTA Market Expansion and New Indications:** The primary growth driver for ADC Therapeutics lies in the successful progression and regulatory approval of ZYNLONTA for its ongoing clinical trials. With ZYNLONTA in Phase III for relapsed or refractory DLBCL and Phase II for follicular lymphoma, successful outcomes could significantly expand its approved indications and market penetration. The global market for lymphoma treatments is substantial, estimated to be in the tens of billions of dollars annually, and securing additional approvals would allow ADCT to capture a larger share, potentially within the next 2-5 years, contingent on trial success and regulatory timelines.
• **Advancement of Camidanlumab Tesirine:** Camidanlumab tesirine represents a key pipeline asset, currently in Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Successful advancement through these clinical stages and subsequent regulatory approvals would open new therapeutic areas for the company, diversifying its revenue streams beyond ZYNLONTA. The market for Hodgkin lymphoma and various solid tumors is vast, offering significant growth potential over a 3-7 year horizon if clinical milestones are met and commercialization is achieved.
• **Development of Early-Stage Pipeline Candidates:** The company's early-stage pipeline, including ADCT-602 for acute lymphoblastic leukemia and ADCT-601/ADCT-901 for solid tumors, offers long-term growth prospects. Successful progression of these candidates from Phase Ia into later clinical stages would validate ADC Therapeutics' broader ADC platform and expand its potential therapeutic reach. While these opportunities have a longer timeline, typically 5-10+ years to market, they are crucial for sustained growth and maintaining a robust product portfolio in the competitive oncology space.
• **Strategic Collaborations and Licensing Agreements:** ADC Therapeutics has established collaborations with companies like Genmab A/S and Mitsubishi Tanabe Pharma Corporation. Expanding these partnerships or forming new ones could provide significant growth. Such agreements can offer non-dilutive funding, access to complementary technologies, broader geographic market penetration, and shared development risks. These collaborations can accelerate pipeline development and commercialization efforts, potentially impacting growth within a 1-5 year timeframe by expanding resources and market access for existing or future products.
• **Innovation in ADC Technology and New Targets:** The company's preclinical pipeline, including ADCT-701 and additional ADCT-901 programs for solid tumors, represents an opportunity to develop next-generation ADCs or target novel cancer biomarkers. Continuous innovation in ADC linker technology, payload design, and antibody selection can enhance efficacy and safety, providing a competitive edge. Successfully bringing these novel candidates into clinical development could unlock new, large market segments in oncology over a 7-10+ year horizon, reinforcing ADC Therapeutics' position as a leader in the ADC field.

What Threats Does ADCT Face?

• Clinical trial failures or unexpected adverse events for any of its pipeline candidates, leading to delays or discontinuation.
• Intense competition from other pharmaceutical and biotechnology companies developing ADCs, immunotherapies, and other cancer treatments.
• Regulatory hurdles and potential delays in obtaining market approvals from health authorities.
• Significant capital requirements for ongoing R&D and commercialization, potentially leading to future equity dilution or debt financing.
• Challenges related to intellectual property protection, including patent disputes or the emergence of biosimilars in the long term.

What Are ADCT's Competitive Advantages?

• Proprietary Antibody Drug Conjugate (ADC) technology platform, which includes specialized linker and payload chemistries designed for targeted drug delivery.
• Extensive and diverse pipeline of ADC candidates in various stages of clinical development, from preclinical to Phase III, addressing multiple cancer types.
• Intellectual property protection through patents covering its ADC compounds, manufacturing processes, and therapeutic applications.
• Strategic collaborations with established pharmaceutical and biotech companies, validating its technology and providing access to resources and market expertise.
• First-mover or early-mover advantage in specific ADC-based indications, particularly with its lead product ZYNLONTA in certain lymphoma settings.

What Does ADCT Do?

ADC Therapeutics S.A., incorporated in 2011 and headquartered in Epalinges, Switzerland, operates as a commercial-stage biotechnology company dedicated to the development of novel antibody drug conjugates (ADCs). These specialized biopharmaceutical products are designed to deliver potent cytotoxic agents directly to cancer cells, minimizing systemic toxicity. The company's core mission revolves around addressing unmet medical needs for patients suffering from hematological malignancies and solid tumors through its innovative ADC platform. ADC Therapeutics' flagship product is ZYNLONTA (loncastuximab tesirine-lpyl), which has demonstrated significant progress in its clinical development. ZYNLONTA is currently undergoing a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Furthermore, it is in a Phase III clinical trial when combined with rituximab, targeting relapsed or refractory DLBCL in second-line transplant-ineligible patients. An additional Phase I clinical trial is evaluating ZYNLONTA for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). Beyond ZYNLONTA, the company's robust pipeline includes camidanlumab tesirine, another ADC that has completed a Phase I clinical trial for relapsed or refractory NHL. This candidate is now in a Phase II clinical trial for relapsed or refractory Hodgkin lymphoma and a Phase Ib clinical trial for selected advanced solid tumors. Other promising candidates include ADCT-602, which is in a Phase Ia clinical trial for acute lymphoblastic leukemia, and ADCT-601 and ADCT-901, both in Phase Ia clinical trials for various solid tumors. The preclinical pipeline features ADCT-701 and additional ADCT-901 programs, also aimed at solid tumors. ADC Therapeutics strategically leverages collaborations, holding agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited, to advance its research and development efforts.

What Products and Services Does ADCT Offer?

• Develops Antibody Drug Conjugates (ADCs) for cancer treatment.
• Focuses on therapies for hematological malignancies (blood cancers) and solid tumors.
• Flagship product ZYNLONTA is in clinical trials for various forms of lymphoma, including DLBCL and follicular lymphoma.
• Advances camidanlumab tesirine for Hodgkin lymphoma and selected advanced solid tumors.
• Maintains an early-stage pipeline with candidates like ADCT-602 for acute lymphoblastic leukemia.
• Engages in preclinical research for novel ADC candidates such as ADCT-701 and ADCT-901 for solid tumors.
• Collaborates with other biotechnology and pharmaceutical companies for research, development, and licensing.
• Operates as a commercial-stage biotechnology company, indicating it has at least one approved product or is nearing commercialization.

How Does ADCT Make Money?

• Invests heavily in research and development to discover and advance novel Antibody Drug Conjugates (ADCs) through preclinical and clinical trials.
• Seeks regulatory approval from health authorities for its developed drug candidates, such as ZYNLONTA, to bring them to market.
• Commercializes approved pharmaceutical products, generating revenue through direct sales or through partnerships with larger pharmaceutical companies for distribution.
• Enters into collaboration and licensing agreements with other biotech and pharma firms, potentially receiving upfront payments, milestone payments, and royalties on future sales.
• Focuses on high-value oncology markets where unmet medical needs exist, allowing for premium pricing upon successful product launch.

What Industry Does ADCT Operate In?

ADC Therapeutics S.A. operates within the highly specialized and innovation-driven biotechnology industry, a sub-sector of healthcare. This industry is characterized by extensive research and development, long product development cycles, and significant regulatory hurdles. The company's focus on Antibody Drug Conjugates (ADCs) places it within a rapidly evolving segment of oncology, where targeted therapies are gaining prominence. The competitive landscape includes both large pharmaceutical companies with broad oncology portfolios and smaller, specialized biotech firms also developing ADCs or other novel cancer treatments. Market trends indicate a growing demand for precision medicine and therapies with improved efficacy and reduced side effects, which ADCs are designed to address. ADC Therapeutics positions itself as a leader in ADC technology, aiming to capture market share in specific hematological malignancies and solid tumors, leveraging its proprietary platform and pipeline depth in a sector known for high-stakes clinical development.

Who Are ADCT's Key Customers?

• Oncologists and hematologists who prescribe cancer treatments.
• Hospitals and cancer treatment centers that administer specialized therapies.
• Patients diagnosed with specific hematological malignancies, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Hodgkin lymphoma.
• Patients with various solid tumors for whom existing therapies may be insufficient.
• Healthcare payers and insurance providers who cover the costs of advanced cancer treatments.

Company Profile

ADC Therapeutics SA operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Epalinges, CH. The company is led by CEO Ameet Mallik. ADCT has traded publicly since 2020.

Return on equity for ADC Therapeutics SA stands at 65.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -26.1%, the inverse of the P/E and a quick read on earnings relative to price.

ADCT Valuation & Market Position

Analyst price targets span from $2.00 to $5.00, with a consensus of $3.50. At the current price of $1.13, that implies approximately 210% upside potential. Relative to its peer group, ADCT's quantitative score of 17/100 is below the peer average of 88/100.

Quarterly Financial Performance: ADC Therapeutics SA

Revenue for ADC Therapeutics SA came in at $19.2M during Q2 FY2026, a 3.9% contraction versus the preceding quarter. The company recorded a net loss of $16.6M, with diluted EPS of $-0.11. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, ADCT averaged $-0.17 in diluted EPS.

ADC Therapeutics SA's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.27 places it in the distress zone, a signal of elevated financial risk.

ADC Therapeutics SA has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 15.6% above estimates on average.

Over the past six months, ADC Therapeutics SA insiders filed 10 SEC Form 4 transactions — 6 sales and 4 purchases. On net that is roughly 4.6M shares disposed (about $19.6M), a signal worth weighing alongside the fundamentals.

ADCT Financials

ADCT Latest News

ADCT Analyst Consensus

ADCT MoonshotScore

Latest ADC Therapeutics SA Analysis

Common Questions About ADCT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources